---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-126550"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2024-12-09T23:59:59+00:00"
generated_at: "2026-05-29T05:35:19.116849+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Carisma Therapeutics reduces workforce by 34%, terminates CFO, discontinues lead candidate CT-0525

## Summary
- Reduction of 23 employees (34% of workforce); expects ~$2.7M in one-time termination costs, substantially complete by Q1 2025.
- CFO Richard Morris terminated without cause effective Dec 31, 2024; entitled to 12 months base salary, target bonus, COBRA; retention option accelerated.
- Discontinues lead product CT-0525 (HER2 solid tumor) due to competitive landscape; final patient already enrolled in Phase 1.
- Revised plan focuses on in vivo mRNA/LNP CAR-M programs with Moderna, plus fibrosis, neurodegeneration, and other diseases; potential development of CT-1119.
- Company expects to appoint a consultant as principal financial and accounting officer.

## SEC filing metadata
- accession: 0001104659-24-126550
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2024-12-09T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.05, 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000110465924126550/0001104659-24-126550-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000110465924126550/tm2430483d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-126550
- JSON: https://secwatch.observer/filing/0001104659-24-126550.json
- Plain text: https://secwatch.observer/filing/0001104659-24-126550.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.